Heme oxygenase 1 and renal ischemia and reperfusion injury: the impact of immunosuppressive drug
Goncalves, Giselle Martins
Cenedeze, Marcos Antonio
Feitoza, Carla Quarim
Paula, Carolina Batista de
Macusso, Georgia Daniela
Pinheiro, Helady Sanders
Antunes Teixeira, Vicente de Paula
Reis, Marlene Antonia dos
Camara, Niels Olsen Saraiva
Is part ofInternational Immunopharmacology
MetadataShow full item record
Background: Ischemia and reperfusion injury (IRI) is the main etiology of acute renal failure in native and transplanted kidneys. in the transplantation field, immunosuppressive drugs may play an additional role in acute graft dysfunction. Acute cyclosporine nephrotoxicity (ATN) can result from vasoconstriction of the afferent arterioles, which may exacerbate deceased renal transplantation. HO-1 is a protective gene with anti-inflammatory and anti-apoptotic actions. We investigated whether HO-1 played a role in cyclosporine-induced renal dysfunction in an established model of IRLMethods: Cyclosporine (100 mg/kg) was administered to mice before being subjected to 45 min of ischemia. Blood and kidney samples were collected at 24, 48 and 120 h after surgery. Acute tubular necrosis and tubular regeneration were quantified. HO-1 gene transcripts were amplified by real-time PCR.Results: Animals subjected to IRI presented with impaired renal function that peaked at 24 h (2.05 +/- 0.23 mg/dL), decreasing thereafter. Treatment with cyclosporine caused even more renal dysfunction at 48 h, sustained up to 120 h after reperfusion (1.53 +/- 0.6 mg/dL), when compared to the controls (0.63 +/- 0.09 mg/dL, p < 0,05). Cyclosporine delayed tubular regeneration that was normally higher in controls at day 5 (67.0% vs. 37.6%, p < 0.05). HO-1 was markedly up-regulated after IRI, and its expression was decreased by cyclosporine (2.06 folds). However, prior induction of HO-1 by cobalt protoporphyrin improved renal dysfunction.Conclusions: These results demonstrated that cyclosporine used in ischemic injured organs might also negatively affect post-transplantation recovery. (c) 2006 Elsevier B.V. All rights reserved.
CitationInternational Immunopharmacology. Amsterdam: Elsevier B.V., v. 6, n. 13-14, p. 1966-1972, 2006.
- EPM - Artigos